NXTC CIK: 1661059

NextCure, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−57.3
FY22:
−53.9
FY23:
−53.0
FY24:
−40.8
FY25:
−49.6
Change from FY21 to FY25
millions USD
FY21:
36.6
FY22:
68.0
FY23:
39.3
FY24:
55.3
FY25:
25.6
Change from FY21 to FY25
millions USD
FY21:
−3.27
FY22:
0.20
FY23:
0.15
FY24:
0.14
FY25:
22.3
millions USD
FY21:
−23.9
FY22:
14.3
FY23:
−13.5
FY24:
14.6
FY25:
−1.75
(positive)
Change from FY21 to FY24
millions USD
FY21:
−59.6
FY22:
−56.0
FY23:
−53.8
FY24:
−41.3
FY25:
–

All amounts in millions USD Data source:SEC EDGAR